ArticleThe Journal of infectious diseases2025
A Plasma Metabolic Signature to Diagnose Pulmonary Tuberculosis and Monitor Treatment Response.
Article in The Journal of infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Host-pathogen interactions in tuberculosis: from immunological mechanisms to translational applications.Cell insight · 2026Review
- Tuberculosis in Pregnancy: Challenges of Immune Protection.The Journal of infectious diseases · 2026Review
- Bridging Ancestry-Stratified Bias in Pharmacogenomics AI: Toward Metabolomics-Inclusive Multi-Omics Precision Medicine.Journal of personalized medicine · 2026Review
- Metabolomic Biomarkers for Monitoring Tuberculosis Treatment Response: A Comprehensive Literature Review.Diagnostics (Basel, Switzerland) · 2026Review
- Targeting Tryptophan Metabolism for Tuberculosis Biomarkers and Host-Directed Therapy.The Journal of infectious diseases · 2026Review
- Multicohort assessment of plasma metabolic signatures of tuberculosis disease in children: a retrospective cross-sectional study.Scientific reports · 2026Article
- Metabolomics in Infectious Diseases and Vaccine Response: Insights into Neglected Tropical and Non-Neglected Pathogens.Infectious disease reports · 2026Review
- Metabolic biomarkers differentiate extrapulmonary tuberculosis from pulmonary TB and non-TB pleural effusions.Frontiers in medicine · 2026Article
- CCR4⁺ memory Tregs and PD-1⁺ T cells as novel immunodiagnostic biomarkers for active tuberculosis.BMC infectious diseases · 2025Article
- Multicohort assessment of plasma metabolic signatures of tuberculosis disease in children.Research square · 2025Article
- Metabolic Changes in Zebrafish Larvae Infected withMetabolites · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
Abstract
backgroundHigh-resolution metabolomics has shown promise for identifying blood-based biomarkers of tuberculosis (TB). We sought to discover a metabolic signature to detect pulmonary TB disease and monitor treatment response.
methodsPlasma from Ethiopian persons with pulmonary TB at diagnosis (n = 82) was compared to household contacts with TB symptoms (n = 104) and 2, 6, and 12 months after treatment initiation. Participants were divided into training and test sets for model building, with additional validation using independent cohorts from the countries of Georgia (n = 89) and South Africa (n = 85). Signatures were further evaluated in nonhuman primates infected with Mycobacterium tuberculosis (Mtb).
resultsAmong the metabolites that most significantly differed in concentration, tryptophan (Trp) and retinol were significantly decreased in persons with TB disease (45.2 vs 62.5 μM and 4.1 vs 8.2 μM, respectively), while kynurenine (Kyn) was significantly increased (2.1 vs 1.6 μM; q < .0001 for all). A signature that included the Kyn/Trp ratio and retinol showed excellent classification for TB disease (area under the curve [AUC] = 0.97). The signature had an AUC of 0.97 in HIV-positive and 0.95 in HIV-negative persons with TB disease from South Africa and 0.93 in TB patients from Georgia. In Ethiopian participants, signature scores decreased after 2 months (0.85 to 0.42) and 6 months of TB treatment (0.42 to 0.18; P < .0001 for both) to similar levels as controls. Plasma retinol also declined in nonhuman primates infected with Mtb 15-16 weeks after infection (5.9 vs 3.6 μM; P < .001).
conclusionsThe plasma Kyn/Trp ratio and retinol represents a promising metabolic signature that could advance TB diagnostics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.